Takeda Looks To The New As It Braces For Velcade Generics

Takeda is facing major revenue challenges from US generics to its big seller Velcade, but is looking to successor and other new products to more than plug the gap.

Two businessmen pulling a rope, closeup shot tug of war
GENERIC VELCADE CHALLENGES LOOM IN US • Source: Shutterstock

Takeda Pharmaceutical Co. Ltd. is bracing for “significant penetration of generic product” for its blockbuster multiple myeloma drug Velcade (bortezomib) in the US, particularly with the advent of the first such competitors in a subcutaneous formulation.

The proteasome inhibitor generated global sales of JPY137.3bn ($1.24bn) - including JPY113.7bn in the US - in the fiscal year...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip